NLRP3 and sickle cell disease: In addition, Epeleuton (15 hydroxy eicosapentaenoic acid ethyl ester) is a novel, orally administered, second-generation omega-3 fatty acid with a favorable clinical safety profile, which found to prevent hypoxia/reoxygenation-induced activation of nuclear factor-κB with downregulation of the NLRP3 inflammasome in lung, kidney, and liver in a mouse model of sickle cell disease [94].